- Home
- CRVS vs HLLY Comparison
CRVS vs HLLY Comparison
Compare CRVS & HLLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- HLLY
- Stock Information
- Founded
- CRVS 2014
- HLLY 1903
- Country
- CRVS United States
- HLLY United States
- Employees
- CRVS N/A
- HLLY N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- HLLY Auto Parts:O.E.M.
- Sector
- CRVS Health Care
- HLLY Consumer Discretionary
- Exchange
- CRVS Nasdaq
- HLLY Nasdaq
- Market Cap
- CRVS 459.0M
- HLLY 437.4M
- IPO Year
- CRVS 2016
- HLLY N/A
- Fundamental
- Price
- CRVS $7.00
- HLLY $3.08
- Analyst Decision
- CRVS Strong Buy
- HLLY Strong Buy
- Analyst Count
- CRVS 3
- HLLY 5
- Target Price
- CRVS $13.00
- HLLY $3.75
- AVG Volume (30 Days)
- CRVS 789.4K
- HLLY 1.0M
- Earning Date
- CRVS 11-11-2025
- HLLY 11-07-2025
- Dividend Yield
- CRVS N/A
- HLLY N/A
- EPS Growth
- CRVS N/A
- HLLY N/A
- EPS
- CRVS N/A
- HLLY N/A
- Revenue
- CRVS N/A
- HLLY $593,797,000.00
- Revenue This Year
- CRVS N/A
- HLLY $0.19
- Revenue Next Year
- CRVS N/A
- HLLY $5.09
- P/E Ratio
- CRVS N/A
- HLLY N/A
- Revenue Growth
- CRVS N/A
- HLLY N/A
- 52 Week Low
- CRVS $2.54
- HLLY $1.60
- 52 Week High
- CRVS $10.00
- HLLY $4.10
- Technical
- Relative Strength Index (RSI)
- CRVS 58.81
- HLLY 38.69
- Support Level
- CRVS $6.65
- HLLY $2.93
- Resistance Level
- CRVS $7.39
- HLLY $3.16
- Average True Range (ATR)
- CRVS 0.42
- HLLY 0.13
- MACD
- CRVS -0.04
- HLLY -0.04
- Stochastic Oscillator
- CRVS 55.47
- HLLY 11.21
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About HLLY Holley Inc.
Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.